Jim Simons Kempharm, Inc Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	N/A	-42,600 Reduced 27.41%	112,800 $557,000
Q1 2024 May 13, 2024	SELL	N/A	-15,100 Reduced 8.86%	155,400 $901,000
Q4 2023 Feb 13, 2024	BUY	N/A	37,800 Added 28.49%	170,500 $1.12 Million
Q3 2023 Nov 14, 2023	BUY	N/A	800 Added 0.61%	132,700 $640,000
Q2 2023 Aug 11, 2023	BUY	$4.94 - $6.29 $138,814 - $176,749	28,100 Added 27.07%	131,900 $673,000
Q1 2023 May 12, 2023	BUY	$4.13 - $6.27 $94,164 - $142,956	22,800 Added 28.15%	103,800 $571,000
Q4 2022 Feb 13, 2023	BUY	$4.12 - $5.62 $37,492 - $51,142	9,100 Added 12.66%	81,000 $372,000
Q3 2022 Nov 14, 2022	SELL	$4.5 - $6.85 $141,723 - $215,733	-31,494 Reduced 30.46%	71,900 $449,000
Q2 2022 Aug 12, 2022	SELL	$4.02 - $5.21 $311,135 - $403,238	-77,397 Reduced 42.81%	103,394 $461,000
Q1 2022 May 13, 2022	BUY	$5.0 - $9.26 $811,455 - $1.5 Million	162,291 Added 877.25%	180,791 $909,000
Q4 2021 Feb 11, 2022	SELL	$7.6 - $10.26 $1.12 Million - $1.51 Million	-147,100 Reduced 88.83%	18,500 $161,000
Q3 2021 Nov 12, 2021	BUY	$8.72 - $13.31 $1.44 Million - $2.2 Million	165,600 New	165,600 $1.55 Million

106

16.8M

220K

38.5K

Ticker KMPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,493,600
Market Cap $170M
Description
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.